Compare Adaptive Biotechnologies Corp (ADPT) vs Citigroup Inc. (C) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Citigroup Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $25.15 (market cap $4.04B), while Citigroup Inc. trades at $137.73 (market cap $227.75B). The key difference: Citigroup Inc. is far larger — about 56.4× Adaptive Biotechnologies Corp's market cap, and Citigroup Inc. pays a 1.97% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | C | |
|---|---|---|
Market Cap | $4.04B | $227.75B |
Sector | Health | Financials |
52-Week High | $25.45 | $145.67 |
52-Week Low | $12.30 | $92.59 |
Enterprise Value | $4.10B | — |
Dividend Yield | — | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
Citigroup (C) trades at $135.22, up 0.17% with bullish technical signals and strong fundamental momentum. The stock shows robust earnings performance with Q1 and Q2 2026 beats, revenue growth to $85.21B in 2025, and improving profit margins. Analyst consensus is strongly bullish with a $154.38 price target, supported by recent strategic hires and digital transformation initiatives.
Outlook remains positive with revenue projected to reach $91.4B in 2026 and net income margin expanding to 19.52%. Key risks include volatile cash flow patterns and high debt levels. The current valuation at 14.63 P/E offers attractive upside potential relative to analyst targets, though investors should monitor execution of the bank's transformation strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Citigroup Inc.
Citigroup Inc. is a diversified financial services holding company that provides a broad range of financial services to consumer and corporate customers. The Company services include investment banking, retail brokerage, corporate banking, and cash management products and services. Citigroup serves customers globally.
Read more on C →
